Mackay Shields LLC Reduces Stake in ANI Pharmaceuticals Inc (NASDAQ:ANIP)

Mackay Shields LLC lessened its position in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 1.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 47,527 shares of the specialty pharmaceutical company’s stock after selling 800 shares during the quarter. Mackay Shields LLC’s holdings in ANI Pharmaceuticals were worth $3,464,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in ANIP. Invesco Ltd. grew its stake in ANI Pharmaceuticals by 113.9% during the 2nd quarter. Invesco Ltd. now owns 214,240 shares of the specialty pharmaceutical company’s stock worth $17,611,000 after buying an additional 114,084 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in ANI Pharmaceuticals during the 3rd quarter worth approximately $7,028,000. Nomura Holdings Inc. grew its stake in ANI Pharmaceuticals by 34.1% during the 2nd quarter. Nomura Holdings Inc. now owns 375,449 shares of the specialty pharmaceutical company’s stock worth $31,071,000 after buying an additional 95,462 shares during the last quarter. Renaissance Technologies LLC grew its stake in ANI Pharmaceuticals by 44.6% during the 2nd quarter. Renaissance Technologies LLC now owns 288,100 shares of the specialty pharmaceutical company’s stock worth $23,682,000 after buying an additional 88,900 shares during the last quarter. Finally, Nuveen Asset Management LLC purchased a new position in ANI Pharmaceuticals during the 2nd quarter worth approximately $7,071,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

ANI Pharmaceuticals stock traded up $1.06 during mid-day trading on Tuesday, reaching $58.42. 5,330 shares of the company were exchanged, compared to its average volume of 273,388. ANI Pharmaceuticals Inc has a twelve month low of $36.92 and a twelve month high of $86.96. The firm’s 50-day simple moving average is $73.05 and its two-hundred day simple moving average is $73.47. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a market cap of $694.07 million, a PE ratio of 12.67 and a beta of 2.20.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.20). ANI Pharmaceuticals had a return on equity of 28.28% and a net margin of 7.58%. The company had revenue of $51.30 million for the quarter, compared to analyst estimates of $56.10 million. During the same period in the previous year, the business posted $1.29 earnings per share. The firm’s revenue was up 1.2% compared to the same quarter last year. As a group, equities research analysts anticipate that ANI Pharmaceuticals Inc will post 4.95 EPS for the current year.

A number of analysts have weighed in on ANIP shares. Raymond James decreased their price objective on ANI Pharmaceuticals from $82.00 to $75.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Zacks Investment Research raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, October 4th. Guggenheim started coverage on ANI Pharmaceuticals in a research report on Thursday, September 12th. They set a “buy” rating and a $76.00 price objective for the company. ValuEngine cut ANI Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 7th. Finally, BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $85.00.

In other news, major shareholder Meridian Venture Partners Ii L sold 9,315 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $69.34, for a total value of $645,902.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 24.70% of the stock is currently owned by company insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Read More: Stock Symbols and CUSIP Explained

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.